Arcus Biosciences reported second-quarter 2026 financial results, posting a net loss of $91 million compared to break-even in the prior year period. Revenues declined to $41 million from $160 million due to the absence of a $143 million cumulative catch-up payment recognized in 2025 related to the pausing of the etrumadenant program. The company holds $775 million in cash and expects full-year revenue between $65 million and $75 million, with sufficient liquidity through at least the second half of 2028. Arcus announced three new clinical collaborations for its lead asset casdatifan involving Bristol Myers Squibb, Summit Therapeutics, and AVEO Oncology to evaluate combinations in clear cell renal cell carcinoma. Additionally, Gilead relinquished its three Board seats following the discontinuation of domvanalimab Phase 3 trials.